Moreover, evidence of the downregulation of the glial glutamatergic transporter EAAT2 in disease-affected areas, both in human sporadic ALS and in transgenic mice for mutated SOD1, led to the hypothesis of its role in ALS progression [58,59]. The gene discussed is SOD1; the disease is amyotrophic lateral sclerosis.